BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 20726318)

  • 1. Prognostic implication of N-RAS gene mutations in Egyptian adult acute myeloid leukemia.
    Elghannam DM; Abousamra NK; Shahin DA; Goda EF; Azzam H; Azmy E; El-Din MS; El-Refaei MF
    Egypt J Immunol; 2009; 16(1):9-15. PubMed ID: 20726318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia.
    Reuter CW; Krauter J; Onono FO; Bunke T; Damm F; Thol F; Wagner K; Göhring G; Schlegelberger B; Heuser M; Ganser A; Morgan MA
    Ann Hematol; 2014 Jun; 93(6):977-82. PubMed ID: 24737308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
    Kiyoi H; Naoe T; Nakano Y; Yokota S; Minami S; Miyawaki S; Asou N; Kuriyama K; Jinnai I; Shimazaki C; Akiyama H; Saito K; Oh H; Motoji T; Omoto E; Saito H; Ohno R; Ueda R
    Blood; 1999 May; 93(9):3074-80. PubMed ID: 10216104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia.
    Coghlan DW; Morley AA; Matthews JP; Bishop JF
    Leukemia; 1994 Oct; 8(10):1682-7. PubMed ID: 7934163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia.
    Ibrahem L; Mahfouz R; Elhelw L; Abdsalam EM; Soliman R
    Blood Cells Mol Dis; 2015 Jan; 54(1):84-9. PubMed ID: 25172541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia.
    Lee YY; Kim WS; Bang YJ; Jung CW; Park S; Yoon WJ; Cho KS; Kim IS; Jung TJ; Choi IY
    Stem Cells; 1995 Sep; 13(5):556-63. PubMed ID: 8528106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
    Ferrara F; Izzo T; Criscuolo C; Riccardi C; Celentano M; Mele G
    Am J Hematol; 2010 Sep; 85(9):687-90. PubMed ID: 20652967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
    Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
    Zidan MA; Kamal Shaaban HM; Elghannam DM
    Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    DiNardo CD; Garcia-Manero G; Pierce S; Nazha A; Bueso-Ramos C; Jabbour E; Ravandi F; Cortes J; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):227-32. PubMed ID: 26799610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.
    Kuo MC; Liang DC; Huang CF; Shih YS; Wu JH; Lin TL; Shih LY
    Leukemia; 2009 Aug; 23(8):1426-31. PubMed ID: 19282830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome.
    Paquette RL; Landaw EM; Pierre RV; Kahan J; Lübbert M; Lazcano O; Isaac G; McCormick F; Koeffler HP
    Blood; 1993 Jul; 82(2):590-9. PubMed ID: 8329714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia.
    Neubauer A; Dodge RK; George SL; Davey FR; Silver RT; Schiffer CA; Mayer RJ; Ball ED; Wurster-Hill D; Bloomfield CD
    Blood; 1994 Mar; 83(6):1603-11. PubMed ID: 8123851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lu D; Nounou R; Beran M; Estey E; Manshouri T; Kantarjian H; Keating MJ; Albitar M
    Cancer; 2003 Jan; 97(2):441-9. PubMed ID: 12518368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.